Venus Medtech (Hangzhou) (HKSE:02500) Interest Expense : HK$-68.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Venus Medtech (Hangzhou)'s interest expense for the six months ended in Dec. 2023 was HK$ -34.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-68.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Venus Medtech (Hangzhou)'s Operating Income for the six months ended in Dec. 2023 was HK$ -264.5 Mil. Venus Medtech (Hangzhou)'s Interest Expense for the six months ended in Dec. 2023 was HK$ -34.5 Mil. Venus Medtech (Hangzhou) did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Venus Medtech (Hangzhou) Interest Expense Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Interest Expense Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-10.03

-2.56

-2.33

-49.83

-68.60

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial							-1.13	-21.57	-29.28	-34.11	-34.49

Venus Medtech (Hangzhou) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-68.6 Mil.

Venus Medtech (Hangzhou) (HKSE:02500) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Venus Medtech (Hangzhou)'s Interest Expense for the six months ended in Dec. 2023 was HK$-34.5 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-264.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$362.6 Mil.

Venus Medtech (Hangzhou)'s Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Venus Medtech (Hangzhou) did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines